πŸ‡ΊπŸ‡Έ FDA
Patent

US 11667637

Fused imidazo-piperidine JAK inhibitors

granted A61KA61K31/437A61P

Quick answer

US patent 11667637 (Fused imidazo-piperidine JAK inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/437, A61P, A61P11/00, A61P11/06